UA72884C2 - Стабілізовані розчини паратирину - Google Patents

Стабілізовані розчини паратирину

Info

Publication number
UA72884C2
UA72884C2 UA2000074034A UA2000074034A UA72884C2 UA 72884 C2 UA72884 C2 UA 72884C2 UA 2000074034 A UA2000074034 A UA 2000074034A UA 2000074034 A UA2000074034 A UA 2000074034A UA 72884 C2 UA72884 C2 UA 72884C2
Authority
UA
Ukraine
Prior art keywords
parathyrine
stabilized solutions
excipient
stabilized
buffering agent
Prior art date
Application number
UA2000074034A
Other languages
English (en)
Russian (ru)
Inventor
Чін-Мінг Ченг
Генрі Екен Хевел
Original Assignee
Елі Ліллі Енд Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22086574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA72884(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Елі Ліллі Енд Компані filed Critical Елі Ліллі Енд Компані
Publication of UA72884C2 publication Critical patent/UA72884C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

Описано стабілізовану фармацевтичну композицію паратиреоїдного гормону у формі розчину для парентерального введення, де терапевтично активний інгредієнт стабілізовано буфером та поліолом. До складу переважних препаратів входять водний розчин людського РТН (1-34), маніт, цитратний, ацетатний або тартратний буфер.
UA2000074034A 1997-12-09 1998-12-08 Стабілізовані розчини паратирину UA72884C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6907597P 1997-12-09 1997-12-09
PCT/US1998/026043 WO1999029337A1 (en) 1997-12-09 1998-12-08 Stabilized teriparatide solutions

Publications (1)

Publication Number Publication Date
UA72884C2 true UA72884C2 (uk) 2005-05-16

Family

ID=22086574

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2000074034A UA72884C2 (uk) 1997-12-09 1998-12-08 Стабілізовані розчини паратирину

Country Status (32)

Country Link
EP (2) EP0920873B1 (uk)
JP (1) JP4405666B2 (uk)
KR (1) KR100482703B1 (uk)
CN (1) CN1198644C (uk)
AR (1) AR018526A1 (uk)
AT (1) ATE260113T1 (uk)
AU (1) AU759726B2 (uk)
BR (1) BR9813463A (uk)
CA (1) CA2314313C (uk)
CY (1) CY1114000T1 (uk)
CZ (1) CZ302401B6 (uk)
DE (1) DE69821872T2 (uk)
DK (2) DK1417972T4 (uk)
EA (1) EA004761B1 (uk)
EG (1) EG23675A (uk)
ES (2) ES2405994T5 (uk)
HK (1) HK1021798A1 (uk)
HU (1) HU230784B1 (uk)
ID (1) ID27741A (uk)
IL (1) IL136662A (uk)
MY (1) MY120063A (uk)
NO (1) NO327302B1 (uk)
NZ (1) NZ505222A (uk)
PE (1) PE20000001A1 (uk)
PL (1) PL194268B1 (uk)
PT (2) PT1417972E (uk)
SK (1) SK288203B6 (uk)
TR (1) TR200002134T2 (uk)
TW (1) TW570811B (uk)
UA (1) UA72884C2 (uk)
WO (1) WO1999029337A1 (uk)
ZA (1) ZA9811127B (uk)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL346127A1 (en) * 1998-07-23 2002-01-28 Lilly Co Eli Fsh and fsh variant formulations, products and methods
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
DZ2873A1 (fr) 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
CA2380423A1 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
IL147731A0 (en) * 2000-05-19 2002-08-14 Bionebraska Inc Peptide pharmaceutical formulations
US20040156835A1 (en) * 2001-05-30 2004-08-12 Taiji Imoto Protein preparation
US20040242489A1 (en) * 2001-11-05 2004-12-02 Mitlak Bruce Howard Method for improving stability of a bone-connecting implant
EP1767213A3 (en) * 2001-11-05 2007-04-25 Eli Lilly & Company Method for improving stability of a bone-connecting implant
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
AU2004226666B9 (en) 2003-04-02 2010-04-08 Ares Trading S.A. Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
JP4871124B2 (ja) 2003-06-20 2012-02-08 アレス トレーディング ソシエテ アノニム 凍結乾燥ｆｓｈ／ｌｈ製剤
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
JP4869077B2 (ja) 2003-12-23 2012-02-01 インフィニティー ディスカヴァリー インコーポレイテッド 癌治療に使用するベンゾキノン包含アンサマイシン類のアナログ
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
EP1789075A4 (en) * 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US8642564B2 (en) 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
CA2628945A1 (en) 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
CN102274492B (zh) * 2006-10-03 2014-11-26 半径健康公司 骨合成代谢蛋白质的药物递送方法
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
JP2010523710A (ja) * 2007-04-12 2010-07-15 インフィニティ・ディスカバリー・インコーポレイテッド ヒドロキノンアンサマイシン製剤
US20080299228A1 (en) * 2007-05-29 2008-12-04 Alan Gerald Harris Topical compositions comprising a macromolecule and methods of using same
CA2692165A1 (en) 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
CA2756690C (en) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
EP2348845A4 (en) 2008-10-15 2013-01-23 Infinity Pharmaceuticals Inc ANSAMYCIN HYDROQUINONE COMPOSITIONS
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
ES2663322T3 (es) * 2009-09-09 2018-04-12 Asahi Kasei Pharma Corporation Agente terapéutico/profiláctico que contiene PTH para la osteoporosis, caracterizado porque la PTH se administra una vez por semana en una dosis unitaria de 200 unidades
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012174158A2 (en) 2011-06-14 2012-12-20 Hale Biopharma Ventures, Llc Administration of benzodiazepine
CN102731643A (zh) * 2012-06-26 2012-10-17 深圳翰宇药业股份有限公司 一种治疗骨质疏松多肽的制备方法
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
EP4039253A1 (en) 2015-04-29 2022-08-10 Radius Pharmaceuticals, Inc. Methods of treating cancer
CN106309358A (zh) * 2015-06-29 2017-01-11 成都金凯生物技术有限公司 含有人甲状旁腺激素的药物组合物及其制备方法与用途
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
SG11201806092TA (en) 2016-03-01 2018-08-30 Ascendis Pharma Bone Diseases As Pth prodrugs
US11590207B2 (en) 2016-09-29 2023-02-28 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release PTH compound
KR102611820B1 (ko) 2016-09-29 2023-12-07 아센디스 파마 본 디지즈 에이/에스 낮은 피크 대 트로프 비를 가진 pth 화합물
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
PE20211202A1 (es) 2017-08-24 2021-07-05 Novo Nordisk As Composiciones de glp-1 y sus usos
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
WO2019059303A1 (ja) * 2017-09-22 2019-03-28 旭化成ファーマ株式会社 薬物動態及び／又は安全性に優れるテリパラチド含有液状医薬組成物
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
CN108159404B (zh) * 2018-01-05 2019-08-27 北京博康健基因科技有限公司 重组人甲状旁腺激素制剂及其制备方法
WO2019220654A1 (ja) * 2018-05-17 2019-11-21 旭化成ファーマ株式会社 Ｎ－ホルミルピぺリジン含有量が低減されている、及び／又は、凍結乾燥ケーキの崩潰又は収縮が抑制されている、製剤
WO2020165087A1 (en) * 2019-02-11 2020-08-20 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
CN112439054B (zh) * 2019-08-28 2023-05-16 深圳翰宇药业股份有限公司 一种特立帕肽缓释凝胶注射液及其制备方法
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
US20230190880A1 (en) * 2020-03-30 2023-06-22 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulations of Human Parathyroid Hormone (PTH) and Methods for Producing Same
CN113967249A (zh) * 2021-12-10 2022-01-25 深圳先进技术研究院 甲状旁腺激素在制备治疗男性抑郁症的药物或保健品中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360940A (ja) * 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
JP2505812B2 (ja) * 1987-07-10 1996-06-12 旭化成工業株式会社 ｈ―ＰＴＨ（１―３４）凍結乾燥組成物
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
GB9020544D0 (en) † 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
US5563122A (en) * 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
DE69332105T2 (de) 1992-09-29 2003-03-06 Inhale Therapeutic Systems San Pulmonale abgabe von aktiven fragmenten des parathormons
IT1255723B (it) † 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
DE19538687A1 (de) † 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon

Also Published As

Publication number Publication date
TW570811B (en) 2004-01-11
JP2001525372A (ja) 2001-12-11
AU1717799A (en) 2005-05-16
ATE260113T1 (de) 2004-03-15
BR9813463A (pt) 2000-10-10
PE20000001A1 (es) 2000-01-17
EA004761B1 (ru) 2004-08-26
CA2314313A1 (en) 1999-06-17
CN1281370A (zh) 2001-01-24
PL194268B1 (pl) 2007-05-31
EP0920873A2 (en) 1999-06-09
NO20002945D0 (no) 2000-06-08
CA2314313C (en) 2005-02-08
NO20002945L (no) 2000-07-07
EP0920873A3 (en) 1999-08-04
EA200000629A1 (ru) 2000-12-25
DE69821872T2 (de) 2005-01-05
KR20010032881A (ko) 2001-04-25
SK288203B6 (sk) 2014-07-02
CZ20002115A3 (en) 2001-05-16
ES2405994T3 (es) 2013-06-04
DK1417972T3 (da) 2013-05-13
TR200002134T2 (tr) 2000-11-21
PL340902A1 (en) 2001-03-12
CN1198644C (zh) 2005-04-27
MY120063A (en) 2005-08-30
AR018526A1 (es) 2001-11-28
EP1417972B2 (en) 2018-08-22
HUP0004447A3 (en) 2003-06-30
EP0920873B1 (en) 2004-02-25
ID27741A (id) 2001-04-26
PT920873E (pt) 2004-06-30
JP4405666B2 (ja) 2010-01-27
HK1021798A1 (en) 2000-07-07
NO327302B1 (no) 2009-06-02
WO1999029337A1 (en) 1999-06-17
KR100482703B1 (ko) 2005-04-14
ES2215268T3 (es) 2004-10-01
EP1417972B1 (en) 2013-04-10
ES2405994T5 (es) 2019-01-30
DK1417972T4 (en) 2018-10-22
ZA9811127B (en) 2000-07-11
HUP0004447A2 (hu) 2001-04-28
CZ302401B6 (cs) 2011-05-04
IL136662A (en) 2004-09-27
EP1417972A1 (en) 2004-05-12
DE69821872D1 (de) 2004-04-01
CY1114000T1 (el) 2016-07-27
SK15322000A3 (sk) 2001-05-10
AU759726B2 (en) 2003-04-17
NZ505222A (en) 2003-05-30
PT1417972E (pt) 2013-05-24
IL136662A0 (en) 2001-06-14
HU230784B1 (en) 2018-05-02
DK0920873T3 (da) 2004-06-28
EG23675A (en) 2007-04-15

Similar Documents

Publication Publication Date Title
UA72884C2 (uk) Стабілізовані розчини паратирину
MX9502034A (es) Formulacion estable, liofilizada, que comprende una proteina y equipo de dosificacion.
HK1018396A1 (en) Delivery system of an active agent.
GB9217312D0 (en) New formulations
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
IL134293A0 (en) Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
NO865079D0 (no) Stabiliserte humanvev-plaminogenaktivator-preparater.
TW200503754A (en) HSA-free stabilized interferon liquid formulations
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
GR3034309T3 (en) IFN--g(b) LIQUID FORMULATIONS
ZA971663B (en) Porcine reproductive and respiratory syndrome vaccine.
HU904007D0 (en) Medical preparations providing regulated active agent discharge and processes for the preparation thereof
ATE553121T1 (de) Verbindungen zur veränderung der schleimsekretion
GB0028130D0 (en) Polypeptide and uses thereof
DE69835167T8 (de) 1,2,4-benzotriazin-oxide enthaltende zubereitungen
UA42741C2 (uk) Пептид маститної вакцини (варіанти), пептид складного антигенного представлення (варіанти), фармацевтична композиція (варіанти)
ES2131482A1 (es) Formulacion acuosa de bambuterol.
HK1047037A1 (en) Pharmaceutical preparations containing nanosols ofchitosan, and their preparation.
EP0586154A3 (en) Melanin-inhibiting protein, its production and applications.
HUP0104623A3 (en) Cyclosporin solution, pharmaceutical composition comprising thereof and its use
FI964448A0 (fi) Uusi biologisesti aktiivinen peptidi ja sen valmistus
WO2002066513A3 (de) Humane zirkulierende lekti fragmente hf7072, hf7638 und hf14448 sowie ihre verwendung
孙绪生 et al. EskoLansimies
ES2130069A1 (es) Preparacion farmaceutica con liberacion retardada del producto activo.